Concepedia

Christie Fanton

CF

17

Publications

1.2K

Citations

15

H-Index

1993

Active since

Affiliations

Nektar Therapeutics (United States)(Current)

The University of Texas MD Anderson Cancer Center

University of New Haven

Novartis (Switzerland)

Novartis (United States)

Christie Fanton is an author at Nektar Therapeutics (United States) specializing in medicine, tumor microenvironment, and tumor biology.

Top concepts

Publications per year

1993–2024

17

Publications

17

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Adi Diab, Nizar M. Tannir, Salah-Eddine Bentebibel et al. · Cancer Discovery · 2020 · 231 citations · Full text

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

Salah-Eddine Bentebibel, Michael E. Hurwitz, Chantale Bernatchez et al. · Cancer Discovery · 2019 · 228 citations

The 31-kDa precursor of interleukin 1 alpha is myristoylated on specific lysines within the 16-kDa N-terminal propiece.

Frazier T. Stevenson, Stuart L. Bursten, Christie Fanton et al. · Proceedings of the National Academy of Sciences · 1993 · 149 citations · Full text

, , +19

Induction of Tubulogenesis in Telomerase-Immortalized Human Microvascular Endothelial Cells by Glioblastoma Cells

Eleni Venetsanakos, Amer M. Mirza, Christie Fanton et al. · Experimental Cell Research · 2002 · 110 citations

, , +9

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Pablo D. García, John L. Langowski, Yingyun Wang et al. · Clinical Cancer Research · 2014 · 110 citations · Full text

Rows per page

1–5 of 17